TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27780630

Group type: EXPERIMENTAL
Intervention: Tdap administered 3-4 weeks before PCV13 and MCV4 (Group A)
Number of subjects: 111

Group type: COMPARATOR
Intervention: All three vaccines administered on the same day (Group B)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: PCV13 and MCV4 administered 3-4 weeks before Tdap (Group C)
Number of subjects: 111
Study: 23932933

Group type: EXPERIMENTAL
Intervention: Caffeine (3mgkg(‐1) BW)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 22077933

Group type: EXPERIMENTAL
Intervention: Short-stretch compression (SSB)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Four-layer compression bandaging (4LB)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 321
Study: 20562669

Group type: EXPERIMENTAL
Intervention: Contact lenses
Number of subjects: 484

Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 484
Study: 17968381

Group type: EXPERIMENTAL
Intervention: Third weight fluctuation tertile
Number of subjects: 3553

Group type: EXPERIMENTAL
Intervention: No weight fluctuations
Number of subjects: 3553

Group type: EXPERIMENTAL
Intervention: Weight fluctuations (WF)
Number of subjects: 3553

Group type: EXPERIMENTAL
Intervention: Weight gain during follow-up
Number of subjects: 3553

Group type: EXPERIMENTAL
Intervention: MS components (raised blood pressure, low HDL-cholesterol, increased waist circumference)
Number of subjects: 3553
Study: 17057785

Group type: EXPERIMENTAL
Intervention: Alternating occlusion (full-time and symmetric for no amblyopia, asymmetric for amblyopia)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No occlusion
Number of subjects: 44
Study: 12701653

Group type: EXPERIMENTAL
Intervention: Mind/body intervention (6-week program with 6 sessions of 90 minutes each)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 128
Study: 10394962

Group type: EXPERIMENTAL
Intervention: Ifosfamide (1,500 mg/m2 over 5 days intravenously)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Temozolomide (100-200 mg/m2 over 5 days orally)
Number of subjects: 20
Study: 8775039

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 2148150

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg three times daily for 4 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 6996931

Group type: EXPERIMENTAL
Intervention: 500 mg dipyrone
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: 500 mg paracetamol
Number of subjects: 299
Study: 31260565

Group type: EXPERIMENTAL
Intervention: BIOCHIP test for bullous pemphigoid (BP)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: BIOCHIP test for pemphigus foliaceus (PF)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: BIOCHIP test for pemphigus vulgaris (PV)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Direct immunofluorescence (DIF)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Indirect immunofluorescence (IIF)
Number of subjects: 69

Group type: COMPARATOR
Intervention: ELISA
Number of subjects: 69
Study: 31342823

Group type: EXPERIMENTAL
Intervention: Virtual reality distraction during dressing change plus standard pharmacological analgesic intervention
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard pharmacological analgesic intervention during dressing change
Number of subjects: 182
Study: 28708873

Group type: EXPERIMENTAL
Intervention: Early cART for two years
Number of subjects: 19
Study: 24938927

Group type: EXPERIMENTAL
Intervention: Pelvic compression belt
Number of subjects: 49

Group type: COMPARATOR
Intervention: No pelvic compression belt
Number of subjects: 49
Study: 23388358

Group type: EXPERIMENTAL
Intervention: Modified WHO hand rub formulations with higher alcohol concentration (5% increase) and lower glycerol concentration (0.725%)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Modified WHO hand rub formulations without glycerol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Reference hand antisepsis procedure
Number of subjects: 25
Study: 20980992

Group type: EXPERIMENTAL
Intervention: Oxycodone (0, 10, 20, 40, and 60 mg/70 kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine/naloxone (Bup/Nx; 2/0.5, 8/2, and 16/4 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 18
Study: 18544181

Group type: EXPERIMENTAL
Intervention: venlafaxine ER
Number of subjects: 687
Study: 17103296

Group type: EXPERIMENTAL
Intervention: Combination of resistance and balance-jumping training (COMB)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Resistance training (RES)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Balance-jumping training (BAL)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Training at least twice a week in COMB group
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 149
Study: 15312856

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 407

Group type: COMPARATOR
Intervention: Comparison of PCI and CABG
Number of subjects: 407
Study: 10858838

Group type: EXPERIMENTAL
Intervention: Midazolam coinduction (0.05 mg/kg BW midazolam, 2.5 micrograms/kg BW fentanyl, 1.0 mg/kg BW propofol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (2.5 micrograms/kg BW fentanyl and 2.0 mg/kg BW propofol)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Midazolam coinduction
Number of subjects: 40
Study: 9350069

Group type: EXPERIMENTAL
Intervention: Moderately salt-restricted diet (5 capsules of placebo)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Salt-supplemented group (5 capsules of 10 mmol sodium per capsule)
Number of subjects: 16
Study: 8462079

Group type: EXPERIMENTAL
Intervention: Fish oil (3.15 g omega-3 fatty acids)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 212
Study: 2951407

Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30391581

Group type: EXPERIMENTAL
Intervention: Test n Treat (TnT) intervention
Number of subjects: 509

Group type: COMPARATOR
Intervention: Control (no TnT)
Number of subjects: 509
Study: 29617940

Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) access
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous (IV) access
Number of subjects: 60
Study: 27655438

Group type: EXPERIMENTAL
Intervention: 10 μg vitamin D3 supplements/d for 20 weeks
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 20 μg vitamin D3 supplements/d for 20 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (0 μg vitamin D3 supplements/d for 20 weeks)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Vitamin D intake to maintain 25(OH)D concentrations >25 nmol/L
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Vitamin D intake to maintain 25(OH)D concentrations >30 nmol/L
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Vitamin D intake to maintain 25(OH)D concentrations >40 nmol/L
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Vitamin D intake to maintain 25(OH)D concentrations >50 nmol/L
Number of subjects: 110
Study: 24702663

Group type: EXPERIMENTAL
Intervention: Kids N Fitness(©) program
Number of subjects: 251
Study: 22453571

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 62154
Study: 20041414

Group type: EXPERIMENTAL
Intervention: Blackcurrant oil soft capsule (BOSC) 1.8 g b.i.d. every day for 6 weeks
Number of subjects: 2154

Group type: EXPERIMENTAL
Intervention: Blackcurrant oil soft capsule (BOSC)
Number of subjects: 2154
Study: 19143245

Group type: EXPERIMENTAL
Intervention: Periarticular intraoperative injection of multimodal analgesic drugs
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 76
Study: 15816106

Group type: EXPERIMENTAL
Intervention: Moderately accelerated radiotherapy (5 vs. 6 fx/wk)
Number of subjects: 803
Study: 12415026

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment 0.1 IU/kg/d subcutaneously at bedtime for 2 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo treatment for 2 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 12
Study: 10754618

Group type: EXPERIMENTAL
Intervention: Clevidipine 20 min infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clevidipine 24 h infusion
Number of subjects: 12
Study: 8771866

Group type: EXPERIMENTAL
Intervention: beta‐1,3‐D‐glucan gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 1474987

Group type: EXPERIMENTAL
Intervention: Fenticonazole powder (antifungal treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control treatment)
Number of subjects: 30
Study: 6726012

Group type: EXPERIMENTAL
Intervention: HLI (Human leukocyte interferon) ophthalmic drops (2.4 x 10^6 IU/ml, 50,000 units per drop, administered two times a day for five days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (commercial artificial tear solution)
Number of subjects: 15
Study: 31186260

Group type: EXPERIMENTAL
Intervention: Single-session educational intervention tailored for ethnic- and gender-specific groups to increase men's social support for their female partners to receive a Pap test.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preexisting brochures on Pap testing (for women) or general men's health (for men)
Number of subjects: 0
Study: 29121283

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 174

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 174
Study: 26064048

Group type: EXPERIMENTAL
Intervention: AOM 400 (400 mg once-monthly)
Number of subjects: 662

Group type: COMPARATOR
Intervention: Oral aripiprazole (10-30 mg/d)
Number of subjects: 662

Group type: COMPARATOR
Intervention: AOM 50 mg (subtherapeutic dose)
Number of subjects: 662
Study: 23796315

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Exposure group therapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 97
Study: 21456040

Group type: EXPERIMENTAL
Intervention: DBT-enhanced habit reversal treatment (HRT)
Number of subjects: 10
Study: 18663543

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric banding surgery (LGBS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal weight controls
Number of subjects: 34
Study: 16453051

Group type: EXPERIMENTAL
Intervention: Oral crystalline cyanocobalamin (1,000 microgram per day for at least 1 month)
Number of subjects: 20
Study: 12910570

Group type: EXPERIMENTAL
Intervention: Glucosamine (alone and in combination with chondroitin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chondroitin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11502782

Group type: EXPERIMENTAL
Intervention: 2 g/d oral L-carnitine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4 g/d oral L-carnitine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bone mineral density
Number of subjects: 50
Study: 9422900

Group type: EXPERIMENTAL
Intervention: Prone knee‐chest position with 3 ml of 0.5% bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine side horizontal position with 3 ml of 0.5% bupivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prone knee‐chest position
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine side horizontal position
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 8124913

Group type: EXPERIMENTAL
Intervention: 3 intravenous pulses of 1000 mg methylprednisolone (MP) on alternate days during the first week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 oral pulses of 100 mg prednisolone
Number of subjects: 30

Group type: COMPARATOR
Intervention: No additional corticosteroids
Number of subjects: 30
Study: 3693807

Group type: EXPERIMENTAL
Intervention: Timolol (beta-adrenergic blocker)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (untreated eyes)
Number of subjects: 10
Study: 2717098

Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 30946463

Group type: EXPERIMENTAL
Intervention: Motivated Forgetting (MF) condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nap group in MF condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No-think words recall performance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 29354912

Group type: EXPERIMENTAL
Intervention: Acupuncture plus electroacupuncture (EA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 60
Study: 26174232

Group type: EXPERIMENTAL
Intervention: UPS+TFS fixation
Number of subjects: 40

Group type: COMPARATOR
Intervention: BPS fixation
Number of subjects: 40
Study: 24231454

Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT11), fluorouracil and leucovorin (IFL)
Number of subjects: 627

Group type: COMPARATOR
Intervention: 5-fluorouracil and leucovorin (FU/LV)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: PIK3CA mutation status
Number of subjects: 627
Study: 21941005

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation (CrMS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 18363758

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied twice daily for 2 weeks, then to both sides for 6 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied to L-sides after initial treatment on P-sides
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied to P-sides
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream applied to L-sides
Number of subjects: 18
Study: 16597037

Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine methods (psychotherapy, daub narcotic to glans of penis, and medication for chronic prostatitis)
Number of subjects: 52
Study: 14678093

Group type: EXPERIMENTAL
Intervention: L-arginine (12 g orally daily for up to 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 0
Study: 11305512

Group type: EXPERIMENTAL
Intervention: Pouchitis patients (n = 9)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pouchitis patients (n = 25)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pouchitis patients (n = 15)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non-pouchitis patients (n = 10)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal controls (n = 9)
Number of subjects: 9
Study: 9128305

Group type: EXPERIMENTAL
Intervention: Barrett's esophagus group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Asymptomatic controls
Number of subjects: 79
Study: 7898065

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3594133

Group type: EXPERIMENTAL
Intervention: Fibrin glue biological adhesive system (BAS) applied in Group I (42 patients)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (Group II, 70 patients)
Number of subjects: 112
Study: 31578136

Group type: EXPERIMENTAL
Intervention: Zinc bisglycinate (15 mg elemental zinc)
Number of subjects: 86
Study: 29482636

Group type: EXPERIMENTAL
Intervention: ACT-based Face-to-face (n=70; six group sessions led by a psychologist)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: ACT-based Mobile (n=78; one group session and mobile app)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control (n=71; only the measurements)
Number of subjects: 219
Study: 27485028

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 3 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 6 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 12 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 24 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydrocortisone with RU486 (GR antagonist)
Number of subjects: 40
Study: 24999075

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (LNG-IUD)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (LNG-IUD) + metformin
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (LNG-IUD) + weight loss intervention
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 165
Study: 22651256

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 86

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: siRNA-mediated knockdown of SUMO-1
Number of subjects: 86
Study: 20881062

Group type: EXPERIMENTAL
Intervention: Nutrient-enriched formula (28-43% more protein and 6-12% more energy than control formula)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 243
Study: 18390077

Group type: EXPERIMENTAL
Intervention: 800 microg of vaginal misoprostol
Number of subjects: 113
Study: 16183363

Group type: EXPERIMENTAL
Intervention: Clinical-based intervention (face-to-face counseling session, phone call, and three mailings) for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control period)
Number of subjects: 0
Study: 12586677

Group type: EXPERIMENTAL
Intervention: Interferon beta
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glatiramer
Number of subjects: 0
Study: 11742882

Group type: EXPERIMENTAL
Intervention: SLC10A2 gene analysis in hypertriglyceridemic patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control subjects (unaffected)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transfected COS cells with SLC10A2 mutations
Number of subjects: 20
Study: 9240105

Group type: EXPERIMENTAL
Intervention: Women with poorer health status (RR = 2.39; 95% CI = 1.86, 3.07)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women with asthma (RR = 2.24; CI = 1.31, 3.80)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women reporting poorer health status (1 year, RR = 3.17; CI = 2.04, 4.94; > 1 year, RR = 8.42; CI = 2.20, 12.88)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women with more than 1 year of poverty (RR = 3.28; CI = 1.90, 5.66)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women with obesity (RR = 3.30; CI = 1.44, 7.55)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women with more than 1 year of employment (RR = 0.55; CI = 0.36, 0.86)
Number of subjects: 0
Study: 8215491

Group type: EXPERIMENTAL
Intervention: Oral cyclosporine, 2.5 mg/kg per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral cyclosporine, 1.25 mg/kg per day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral cyclosporine, 3.75 mg/kg per day
Number of subjects: 40
Study: 3317328

Group type: EXPERIMENTAL
Intervention: Cefonicid administered once daily, 1/2 to 1 hour before surgery, continued for up to 72 hours.
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cefazolin administered every eight hours, 1/2 to 1 hour before surgery, continued for up to 72 hours.
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Cefonicid and Cefazolin (both interventions).
Number of subjects: 117
Study: 31804741

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 1000 mg intravenous, administered two weeks apart
Number of subjects: 11

Group type: COMPARATOR
Intervention: Corticosteroid therapy
Number of subjects: 11
Study: 31615573

Group type: EXPERIMENTAL
Intervention: ED-based HSCP assessment and intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual ED care
Number of subjects: 320
Study: 28444779

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 123

Group type: COMPARATOR
Intervention: Thiopentone and desflurane
Number of subjects: 123
Study: 25566763

Group type: EXPERIMENTAL
Intervention: Masivukeni intervention
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard of Care (SOC) counseling
Number of subjects: 55
Study: 23975945

Group type: EXPERIMENTAL
Intervention: PHD testing without anesthesia
Number of subjects: 44

Group type: COMPARATOR
Intervention: PHD testing with anesthesia
Number of subjects: 44
Study: 21406695

Group type: EXPERIMENTAL
Intervention: Superoxidized aqueous solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study: 18982248

Group type: EXPERIMENTAL
Intervention: Tablet administered 45 min before food (pre-feed)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tablet administered on an empty stomach (fasted)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tablet administered after food (fed)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tablet administered pre-feed (in six volunteers)
Number of subjects: 10
Study: 17870483

Group type: EXPERIMENTAL
Intervention: Triage pain protocol
Number of subjects: 800

Group type: COMPARATOR
Intervention: Standard care (prior to protocol)
Number of subjects: 800
Study: 14998240

Group type: EXPERIMENTAL
Intervention: Anxious Cognitive Arousal Group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Neutral Cognitive Arousal Group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Anxious Cognitive Arousal
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Physiological Arousal
Number of subjects: 54

Group type: COMPARATOR
Intervention: No manipulation
Number of subjects: 54
Study: 11290851

Group type: EXPERIMENTAL
Intervention: High school-based alcohol prevention program (n = 1,820)
Number of subjects: 4635

Group type: COMPARATOR
Intervention: Control group (n = 2,815)
Number of subjects: 4635
Study: 9589652

Group type: EXPERIMENTAL
Intervention: rhGH (0.1 mg/kg.day)
Number of subjects: 17
Study: 8061799

Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 38
Study: 2648916

Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 36